| Literature DB >> 27255933 |
Christiaan F Mooij1, Rick Hermsen2, Esther P A H Hoppenreijs3, Chantal P Bleeker-Rovers4, Marloes M IJland5, Lioe-Fee de Geus-Oei2.
Abstract
BACKGROUND: Henoch-Schönlein vasculitis is the most common systemic vasculitis in children. Arthritis or arthralgia occurs in 80 % of patients. We believe this to be the first case report to describe the finding of polyarthritis in a fludeoxyglucose positron emission tomography-computed tomography scan in a patient with Henoch-Schönlein vasculitis without clinical signs of arthritis. CASEEntities:
Keywords: FDG-PET/CT; Henoch-Schönlein; polyarthritis
Mesh:
Substances:
Year: 2016 PMID: 27255933 PMCID: PMC4890487 DOI: 10.1186/s13256-016-0913-8
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
A timeline of events for a 4.5-year-old boy with Henoch-Schönlein vasculitis
| Time point | Event |
|---|---|
| Two week prior to presentation | • Upper respiratory tract infection with a painful throat, no doctor was consulted |
| Day 1 - Presentation | • Presentation to a local hospital with fever without clear focal symptoms |
| Day 4 | • Patient was referred to the university hospital because of possible Kawasaki disease |
| Day 7 | • Treatment with intravenous immunoglobulins for possible incomplete Kawasaki disease |
| Day 8 | • Treatment with intravenous immunoglobulins for possible incomplete Kawasaki disease |
| Day 9 | • Started treatment with diclofenac |
| Day 13 | • FDG-PET/CT: increased FDG uptake in multiple joints (polyarthritis) and multiple bilateral cervical lymph nodes |
| Day 14 | • Ultrasound evaluation of his joints: no signs of arthritis |
| Day 17 | • Clinical improvement with diclofenac treatment |
| Day 24 | • Evaluation at our outpatient clinic |
| Day 25 | • Presentation with bloody stools and abdominal pain |
| Day 35 | • Clinical improvement |
| Day 63 | • Relapse in joint pain and abdominal pain |
| Day 73 | • No clinical signs of Henoch-Schönlein vasculitis |
FDG-PET/CT fludeoxyglucose positron emission tomography-computed tomography, IgA immunoglobulin A
Results of laboratory tests
| Laboratory test | Result | Time of laboratory test |
|---|---|---|
| Hemoglobin | 6.0 mmol/l | Day 6 |
| Leukocytes | 10.9 × 109/l | Day 6 |
| Manual blood count | No abnormalities | Day 6 |
| Alanine aminotransferase (ALAT) | 29 U/l | Day 6 |
| Aspartate aminotransferase (ASAT) | 42 U/l | Day 6 |
| Gamma-glutamyl transpeptidase | 14 U/l | Day 6 |
| Lactate dehydrogenase (LDH) | 370 U/l | Day 6 |
| Creatinine | 25 μmol/l | Day 6 |
| Urea | 5.7 mmol/l | Day 6 |
| Ferritin | 100 μg/l | Day 13 |
| Anti-Nuclear Antibody (ANA) | Weak positive | Day 9 |
| Anti-Neutrophil Cytoplasmic Antibody (ANCA) | Negative | Day 9 |
| IgG | 28.80 g/l | Day 7 |
| Urine test | No proteinuria and no hematuria | Day 4, 9, 12, and 24 |
Fig. 1Maximum intensity projection of the patient. The projection shows increased fludeoxyglucose uptake in multiple joints and at the site of injection in the right lower leg
Fig. 2Detailed image of fludeoxyglucose positron emission tomography-computed tomography scan showing increased fludeoxyglucose uptake in the left ischiopubic tendon attachments (arrow)
Fig. 3Detailed images of fludeoxyglucose positron emission tomography-computed tomography scan showing metabolically active cervical lymph nodes and increased fludeoxyglucose uptake in the left shoulder joint (arrows)